I don't see any barrier to controlling aging. I mean, we've got a few examples. Some of them are cellular, where we can go from 80-year-old human cells to basically embryonic day five type embryo-like cells. We have a few that work at the whole organism level. So I think it's programmed by evolution and can be reprogrammed. I don't think it's easy. It's not something that we can't do now because of all the exponential technologies. I think it's going to go very quickly now.
Welcome to Unnatural Selection, a show about competition, innovation, and the strategy shaping tomorrow's frontiers. I'm Nick Cancina. Each week we speak with pioneers shaping the future. Welcome to episode 23 of Unnatural Selection. Today we're joined by Dr. George Church, a pioneer of the Human Genome Project and one of the founding minds of synthetic biology. We explore how the field has evolved from reading the code of life to rewriting it toward virus-proof humans, de-extinction, and even reprogramming aging itself. Now, as synthetic biology converges with AI and neuromorphic engineering, we ask: are we designing the future of life, or redefining what it means to be human?
George Church is professor of genetics at Harvard Medical School and director of personalgenomes.org, which provides the world's only open access information on human genomic, environmental, and trait data. His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing, and barcoding. These led to the first genome sequence of a pathogen, Helicobacter pylori, in 1994. His innovations have contributed to nearly all next-generation DNA sequencing methods and companies: CG, BGI, Life, Illumina, Nanopore. This, plus his lab's work on chip DNA synthesis, gene editing, and stem cell engineering, resulted in founding additional application-based companies spanning fields of medical diagnostics: Gnome, Pion, DX, Elacris, Nebula, Veritas, and synthetic biology therapeutics: Avitro, Juno, Gen9, Envolve, Zyrgen, Warp Drive, GKO, Adidas, Agenis. He has also pioneered new privacy, biosafety, environmental, and biosecurity policies. He was director of an IARPA BRAIN project and three NIH Centers of Excellence in Genomic Science, 2004–2020. His honors include election to NAS and NAE and Franklin Bower Laureate for achievement in science. He has co-authored 716 papers, 156 patent publications, and a book, Regenesis. Let's go.
George, welcome to Unnatural Selection.
Oh, thank you, Nick. It's great to be here.
It's really an honor to meet you and have this conversation, George. As we've spoken before, I was a part of the Human Genome Project way back in the day, which you helped spearhead and were so influential in, not only the process itself, but the science that led to it. But before going down that road, for the sake of the audience listening, to hear from your perspective, could you please tell us what need or impact drives your work, and how do you view your role in addressing it?
Yeah, I think our role in addressing it is mostly technology development, sort of radical technology development, not incremental. And what we're addressing is various aspects of preventative and curative medicine, in particular age-related diseases. We're interested in sequencing as many humans as want to be sequenced, maybe 8 billion, and the biosphere. This would of course be done collaboratively with lots of groups, and interested in safety and security technology and applications to environmental and climate change problems. So these are all connected by technology.
Absolutely. And for those new to the field, how would you explain synthetic biology and its relationship to genomics?
Right. So genomics classically was analytic, surveying and studying the genomes of diverse organisms, with a slight emphasis on human once the technology worked well enough to get up to that scale. But that was genomics that was mostly analytic. Synthetic biology, as the name implies, is mostly synthetic. It's mostly about writing rather than reading. But you need both of them. You need synthetic biology to make tools for reading. You need the reading in order to know what it is that you're doing as you synthesize. Synthetic biology is a kind of extension of the recombinant DNA revolution in the '70s, but updated with more rigorous engineering principles, more safety engineering components, more developmental biology at one end, and more non-biological synthetic biology at the other end, you know, minerals and organics.
And you mentioned earlier that you're focused on kind of radical leaps forward versus incremental innovation. And you've helped pioneer foundational tools from the Human Genome Project to CRISPR multiplex editing. How do you decide which bold ideas to pursue next, and what makes an idea kind of worth the risk in your mind versus something that could be distracting?
A really excellent question. The question really. It's, well, first of all, I have never really dropped a project. It's just you just dial down the heat a little bit and put it on the wall on display. I think a lot of people have, you know, very creative ideas, but that there's a tendency to reject them more quickly before you've really given them a good chance, and rightly so, because some of them do take a long time or short time with a lot of money. I tend to be cheap. I don't like spending a lot of money. So I consider, you know, I have a fairly low threshold for when it's getting too expensive. And the first thing I do when I enter a challenging field, which everybody might think is high-hanging fruit rather than low, or that it's impossible or useless or both, as a very common description of public or other scientists' opinions of my work when I start out, I think that I try to lower the price as the first step. And it's not, I mean, that doesn't sound, that sounds a little prosaic and ordinary, but it isn't when you start getting up into 20-million-fold changes in price. It changes from something that was just basically an idea toy into something that has whole new properties, like DNA sequencing goes from something that you can do for teeny little RNAs back in the '70s when I started and what got me excited, and I'm still working on 50 years later, to now, you know, whole biospheres and ecosystems and human population. So these are transformative, just the price alone. But the other thing is doing things that just weren't really possible before. You know, like multiplex engineering of mammalian germline and making a virus-resistant cell, you know, making organ transplants from animals to humans. These are applications of those transformative technologies, which sometimes are transformative themselves.
Yeah. And no, I mean, that doesn't sound to me prosaic or mundane at all. I have a big, a long history of being in startups, and I have found that starting with very minimal budgets has an amazing ability to focus the mind on the things that really matter and iterate, versus the opposite extreme, which is like sometimes you have too much money can actually do the opposite. You end up concealing glaring errors that you might have discovered otherwise if you were really counting your pennies. And so I actually, I like that approach. It sounds very startup-y. So, you know, you kind of touched upon how you focus on the ideas and how you were finding them at first. Does your lab operate more like an academic lab, more like a startup environment with teams working on certain topics, or is it some kind of a mix in between? Because your lab has also been very prolific in launching companies, and so does your ecosystem look more like a startup or more like an academic lab, or somewhere in between?
I think it's unapologetically multidisciplinary. Almost everybody in the lab is themselves cross-trained in more than one field. I think it's hard to build a multidisciplinary team with only disciplinarians. And so it does have components that are basic, pure science, even pure engineering sounds like an oxymoron, and then but with a look to what societal needs are and how we could quickly bridge the two. It used to be you had to choose because, you know, everything was so slow. But now, because we've been in exponential technology essentially for my entire career since the '70s, is that now you can do both at once, and you should when you have an... We try to pick things that are both basic, fundamental, philosophical almost, things that involve orders of magnitude of technology, and things that are society-beneficial, and that involves a startup mentality that you mentioned. We don't have a large company mentality. We just can't... I can't wrap my head around it. But occasionally do collaborate with them.
Okay. And if we talk about the science, synthetic biology promises everything from virus-proof humans, as you mentioned, virus-proof cells, to biofuels, de-extinct species, which is something we'll dive into, even aging reversal. Of the radical applications that you're pursuing or have pursued, like genome recoding, cellular rejuvenation, which do you believe are closest to real-world impact and implementation?
Well, yeah, so going to the societal impact edge, I'd say we have one kidney that came from a pig that was engineered in 69. So multiplex editing is the basic engineering. But it's delivered pigs that are human-compatible, their hearts, livers, kidneys, etc. There is at least one patient, the record holder right now from our, from one of our pig kidneys, is getting close to six months. Name is Tim Andrews. He lives in the Boston area. So that's one. We have about 15 different pharmaceuticals, mostly, you know, proteins and gene therapies, but some cell therapies, some small molecules that are in clinical trials or are very close to, that made it through preclinical. So that's another category. We've made new strains of bacteria that have new amino acids in them, and those look like they're ready for industry, but not yet. There's nothing, no product out there in the supermarket. So those are some examples.
That's amazing. And I think the aging one is a really interesting one as well. And there are companies obviously working on this. Do you believe that aging is ultimately something that's programmable, or do you, given there are companies like Calico and others out there that have been working on this for at least a decade, are we seeing boundaries that seem beyond re-engineering, or do you feel that ultimately human aging is something that we can control?
Yeah, I don't see any barrier to controlling aging. I mean, we've got a few examples. Some of them are cellular, where we can go from 80-year-old human cells to basically embryonic, you know, day five type embryo-like cells. We have a few that work at the whole organism level, and among the things that are moving into clinical trials that I mentioned just a second ago, Rejuvenate Bio has two triple gene therapies, each of which looks very promising for reversing specific age-related diseases, which is what FDA cares about, as well as evidence that they're working at a fundamental level of aging because it causes a longevity effect even when delivered very late in life, meaning at the point where half of the animals are dying of age diseases. Yeah, I think it could be reprogrammed. Clearly rodents are about a year or so as their longevity lifespan, had whales, which are also mammals, about 200 years. Humans are pretty long-lived in between those. So I think it's programmed by evolution and it can be reprogrammed. I don't think it's easy. I think that there's been a lot of wishful thinking that it's just some food or maybe two foods or some pill, you know, that's based on natural products, or serendipitously came out of some other study. I think it's much, I think it's harder than that, but it's not something that we can't do now because of all the exponential technologies. I think it's going to go very quickly now. You know, in the same sense there are a lot of really complicated things in the world like, you know, supercomputers and jet engine, jet planes and so forth, that we're good at engineering complicated things, and we now have the tools for engineering complex age-related diseases.
So as an extension of that question then, what does death mean to you? If we're obviously reprogramming kind of like the code of life, it begs the question of what death is. Is it a disease or an illness that can be prevented? Is that the way that, how would you see death then if we can extend life?
Well, I think before we get to preventing death, we're preventing age-related diseases and poor health. So we want to restore youthful physiological functions, and we know a lot of those things that need to be restored. We have kind of lists of all the RNAs and proteins that are required for that youthfulness, and even though it's a long list, we could just put them into cells and show that the cells repair better and just function more youthfully. So that's the big step, and to some extent if that works well enough, then you don't need to talk about death per se, because as long as you stay youthful and stay out of accidents and, you know, an asteroid doesn't hit us, then lack of death comes as a bonus. I think the FDA does not recognize aging as a disease, and I'm okay with accepting their definition because, you know, they're kind of in charge of safety and efficacy for the United States and setting an example for the world. And I don't think we need to define it as a disease in order to get, you know, drugs that reverse one or two age-related diseases by affecting all of them. But you don't need to prove it affects all of them. You just have to prove it for one, and then you have something that as a side benefit will address almost all or all age-related diseases.